Clinical trials in Salamanca – page 19

445 clinical trials in Salamanca, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Salamanca at a glance

445

clinical trials

Research sites1

Quick filters

445 trials in Salamanca

Open in trial search

Colorectal cancer metastatic

Not recruiting

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Contact Research Centre

Acute myeloid leukaemia

Not recruiting

Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

Registered drugNo placebo

Pharmacokinetic, Safety, and Efficacy Evaluation of ASTX727 and Venetoclax in Adult Patients with Acute Myeloid Leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cedazuridine
Sponsor:Taiho Oncology Inc.

Contact Research Centre

Chronic lymphocytic leukaemia+3

Not recruiting

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo

Evaluation of Safety and Efficacy of Zilovertamab Vedotin and Nemtabrutinib in Aggressive and Indolent B-cell Malignancies

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Nemtabrutinib
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Warm autoimmune haemolytic anaemia+1

Not recruiting

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Danazol
Sponsor:Novartis Pharma AG

Contact Research Centre

Colorectal cancer metastatic

Not recruiting

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting

Registered drugNo placebo

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:AstraZeneca AB

Contact Research Centre

Dementia Alzheimer's type

Not recruiting

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo

A Study to Test the Long-term Safety and Benefits of GSK4527226 in Patients with Early Alzheimer's Disease

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:GSK4527226
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Eltrombopag
Sponsor:Novartis Pharma AG

Contact Research Centre

Haematological malignancy+1

Not recruiting

Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

InvestigationalNo placebo

Study of AZD2962 tablets alone and with other medications in patients with myelodysplastic syndromes and dysplastic chronic myelomonocytic leukemia

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease

Not recruiting

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug

Study of vicadrostat and empagliflozin given together or separately in people with chronic kidney disease to test safety and effectiveness

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:BI 690517
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Arteriosclerosis

Not recruiting

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug

Study of pelacarsen and inclisiran in patients with atherosclerotic cardiovascular disease who have high levels of LDL cholesterol and lipoprotein(a)

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Inclisiran
Sponsor:Novartis Pharma AG

Contact Research Centre

Waldenstrom's macroglobulinaemia+1

Not recruiting

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

InvestigationalNo placebo

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Zanubrutinib
Sponsor:BeOne Medicines AG

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Salamanca

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on various types of lymphomas and leukemias, including innovative combination therapies for mantle cell lymphoma and chronic myeloid leukemia. Multiple trials are evaluating novel treatment approaches for both newly diagnosed and refractory cases.

Blood Cancers
Solid Tumors
Targeted Therapies

Research includes promising treatments for pancreatic adenocarcinoma and advanced breast cancer.

02 Respiratory Medicine

Investigations into preventing and treating respiratory syncytial virus infections, with particular focus on vaccine development for older adults. Studies aim to understand immune responses and evaluate preventive strategies.

Viral Infections
Vaccine Development
Elderly Care

Clinical trials emphasize protection for vulnerable populations against respiratory infections.

03 Immunology Studies

Research addressing chronic spontaneous urticaria and autoimmune conditions, including innovative treatments for systemic sclerosis. Studies evaluate new therapeutic approaches for inflammatory conditions.

Autoimmune Disorders
Allergic Conditions
Novel Therapeutics

Trials focus on improving patient outcomes through targeted immunological interventions.

Back to Spain All countries